Although survival of multiple myeloma patients has at least doubled during recent years, most patients eventually relapse. At the time of relapse, the use of alternative drugs to those given upfront is current practice. However, many new options are currently available for the treatment of relapsed multiple myeloma, including recently approved drugs, such as the second- and third-generation proteasome inhibitors (carfilzomib and ixazomib), the second- and third-generation immunomodulatory drugs (lenalidomide and pomalidomide), the monoclonal antibodies (daratumumab and elotuzumab) and the histone deacetylase inhibitor (panobinostat). We here describe new treatment options for relapsed multiple myeloma in Poland based on drugs that can be us...
New drugs introduced in recent years to the therapy of multiple myeloma (MM) patients allow to obtai...
The article is dedicated to pomalidomide efficacy in heavily pretreated patient with a long term his...
Progressive multifocal leukoencephalopathy (PML) is a rare but a very serious complication associate...
Pomalidomide is a new immunomodulatory drug used for treatment of relapsed/refractory plasma cell my...
The introduction of new drugs (immunomodulators, proteasome inhibitors) into the treatment of multip...
During recent years there have been significant developments in the field of diagnostics and therapy...
During nearly two decades there has been continuous progress in the therapy of plasma cell myeloma r...
Multiple myeloma (MM) is a malignant and still incurable proliferative disease of the hematopoietic ...
Introduction of new drugs into therapy of multiple myeloma prolonged significantly progression free ...
New drugs introduced in recent years to the therapy of multiple myeloma patients resulted in better ...
W ostatnich latach dokonał się znaczący postęp w leczeniu szpiczaka plazmocytowego (PCM). Dzięki now...
Myeloma multiplex (MM) is one of the most common haematological malignancies. In recent years, due t...
Pomalidomide is a new immunomodulatory drug used for treatment of plasma cell myeloma (PCM). In this...
W pracy przedstawiono przypadek 63-letniej chorej z drugim nawrotem szpiczaka plazmocytowego po wcze...
The treatment of relapsed and refractory plasma cell myeloma is a real challenge, especially in case...
New drugs introduced in recent years to the therapy of multiple myeloma (MM) patients allow to obtai...
The article is dedicated to pomalidomide efficacy in heavily pretreated patient with a long term his...
Progressive multifocal leukoencephalopathy (PML) is a rare but a very serious complication associate...
Pomalidomide is a new immunomodulatory drug used for treatment of relapsed/refractory plasma cell my...
The introduction of new drugs (immunomodulators, proteasome inhibitors) into the treatment of multip...
During recent years there have been significant developments in the field of diagnostics and therapy...
During nearly two decades there has been continuous progress in the therapy of plasma cell myeloma r...
Multiple myeloma (MM) is a malignant and still incurable proliferative disease of the hematopoietic ...
Introduction of new drugs into therapy of multiple myeloma prolonged significantly progression free ...
New drugs introduced in recent years to the therapy of multiple myeloma patients resulted in better ...
W ostatnich latach dokonał się znaczący postęp w leczeniu szpiczaka plazmocytowego (PCM). Dzięki now...
Myeloma multiplex (MM) is one of the most common haematological malignancies. In recent years, due t...
Pomalidomide is a new immunomodulatory drug used for treatment of plasma cell myeloma (PCM). In this...
W pracy przedstawiono przypadek 63-letniej chorej z drugim nawrotem szpiczaka plazmocytowego po wcze...
The treatment of relapsed and refractory plasma cell myeloma is a real challenge, especially in case...
New drugs introduced in recent years to the therapy of multiple myeloma (MM) patients allow to obtai...
The article is dedicated to pomalidomide efficacy in heavily pretreated patient with a long term his...
Progressive multifocal leukoencephalopathy (PML) is a rare but a very serious complication associate...